妇科肿瘤患者血免疫抑制酸性蛋白水平测定的临床意义

目的测定妇科肿瘤患者血清免疫抑制酸性蛋白（ＩＡＰ）水平,探讨其对妇科肿瘤患者的诊断及随访预后的临床意义。方法采用ＩＡＰ单向免疫扩散法测定２３５例妇科肿瘤患者血清ＩＡＰ水平,其中良性卵巢瘤３８例,卵巢上皮癌４１例,子宫平滑肌瘤６６例,子宫颈癌３４例,子宫内膜癌１６例;卵巢癌术后化疗者２７例,卵巢癌复发者１３例。对照组为５０例健康育龄妇女。结果卵巢癌患者血清ＩＡＰ值为（８８９±２０８）ｍｇ／Ｌ,其水平明显高于健康妇女和良性卵巢瘤组（Ｐ＜０．０１）。子宫颈癌和子宫内膜癌患者血清ＩＡＰ值分别为（７４１±２１３）ｍｇ／Ｌ和（７６３±２０９）ｍｇ／Ｌ,明显高于健康妇女和子宫肌瘤组（Ｐ＜０．０１）。化疗后卵巢癌患者血清ＩＡＰ水平明显下降;卵巢癌术后复发者血清ＩＡＰ水平明显高于健康妇女ＩＡＰ水平（Ｐ＜０．０１）,异常值的发生率为１００％。结论测定妇科肿瘤患者血清免疫抑制酸性蛋白ＩＡＰ水平可作为监测妇科肿瘤和鉴别良恶性肿瘤的一项辅助指标。

Investigation of serum immunosuppresive acidic protein levels in gynecological tumor

OBJECTIVE: To study the clinical significance for measureing serum immunosuppresive acidic protein (IAP) levels to diagnoze and follow up survey patients with the gynecological tumor. METHODS: Serum IAP levels were determined by IAP-single radial immunodiffusion test in 235 patients with gynecological tumor, 38 patients had benign ovary tumor, 41 were malignant ovary tumor, 66 hysteromyoma, 34 cervical carcinoma, 16 endometrial carcinoma, 27 received chemotherapy, and 13 had tumor recurrence. The control group consisted of 50 health women. RESULTS: The serum IAP level was (889 +/- 208) mg/L in malignant ovary tumor, and higher than that of the health women and benign ovary tumor, (P < 0.01). In patients with cervical carcinoma and endometrial carcinoma, the IAP level was (741 +/- 213) and (763 +/- 209) mg/L respectively, and higher than that of the health women and benign ovary tumor (P < 0.01). After chemotherapy, the serum IAP level of malignant ovary tumor was decreased. In patients with recurrence of ovary tumor, the IAP levels was increased to compare with the health women (P < 0.01), the incidence of the abnormal value was 100%. CONCLUSION: Detecting IAP level of the gynecological tumor may be an auxiliary index for monitoring gynecological tumor and identifying whether it is benign or malignant.